Minapharm PharmaceuticalsCAI:MIPH -0.27%41 Pretax Margin % is 2.36% as of Dec. 2025, which is 53% below its 10-year median of 4.99. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 961 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks worse than 59.52% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Minapharm Pharmaceuticals Pretax Margin % Related Terms
Minapharm Pharmaceuticals Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:MIPH vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minapharm Pharmaceuticals (CAI:MIPH) has a Pretax Margin % of 2.36% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Minapharm Pharmaceuticals and its competitors. This is 53% below median its historical median of 4.99. Over the past decade, Minapharm Pharmaceuticals' Pretax Margin % has ranged from 0.85 to 24.32. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #572 out of 961 companies in the Drug Manufacturers industry, placing it in the top 59.5%.
Is Minapharm Pharmaceuticals' Pretax Margin % too high?
Minapharm Pharmaceuticals' current Pretax Margin % of 2.36% is 53% below median its 10-year median of 4.99. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 24.32. The Drug Manufacturers industry median Pretax Margin % is 7.28. Minapharm Pharmaceuticals' value of 2.36% is 67.6% below this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #572 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #572 out of 961 companies for Pretax Margin %. This places Minapharm Pharmaceuticals in the lower half of its industry. The industry median Pretax Margin % is 7.28. Minapharm Pharmaceuticals' value of 2.36% is 67.6% below this benchmark. Historically, Minapharm Pharmaceuticals' own Pretax Margin % has ranged from 0.85 to 24.32 over the past decade. While the company's 10-year median is 4.99 vs. the industry median of 7.28, Minapharm Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current Pretax Margin % of 2.36% is 67.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current Pretax Margin % is 2.36%, which is 53% below median its own 10-year median of 4.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current Pretax Margin % is 2.36%, which is 53% below median its 10-year median of 4.99 and 67.6% below the Drug Manufacturers industry median of 7.28. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Pretax Margin % is 2.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Pretax Margin %: 2.36% (53% below median its 10-year median of 4.99)
GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
Industry Position: 67.6% below the Drug Manufacturers median (#572 of 961)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score
Get the complete analysis for CAI:MIPH
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
